Subscribe
JarTee / Shutterstock.com
10 April 2025NewsBig PharmaMuireann Bolger

AstraZeneca fends off diabetes generic, for now

Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AstraZeneca unit draws line under Samsung dispute
5 September 2024   AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.
Americas
AstraZeneca to buy Alexion for $39bn
14 December 2020   AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.


Editor's picks

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025

Editor's picks

Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025

More on this story

Americas
AstraZeneca unit draws line under Samsung dispute
5 September 2024   AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.
Americas
AstraZeneca to buy Alexion for $39bn
14 December 2020   AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

More on this story

Americas
AstraZeneca unit draws line under Samsung dispute
5 September 2024   AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.
Americas
AstraZeneca to buy Alexion for $39bn
14 December 2020   AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

More features

BMS notches legal win and FDA nod
Patent pledges in global crises: Why Moderna prevailed over Pfizer/BioNTech
EPO: Biotech innovation strong, while pharma trails behind
LSPN chair: Uncertainty lies ahead for life sciences
UPC issues sweeping injunction against Meril in heart valve case
PierFerd taps pharma and biotech patent expert from Weiss & Arons
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
Mental health IP toolkit: Diversity Champ’s stress-busting tips